Rhythm Pharmaceuticals Announces IMCIVREE(R) (setmelanotide) Receives Expanded Marketing Authorization In The United Kingdom For Treatment Of Obesity And Control Of Hunger In Patients With Acquired Hypothalamic Obesity Due To Hypothalamic Injury Or Impairment >RYTM

Dow Jones2026/08/11 12:00

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.